Critical Heart Failure drug gets Cheaper, JB Pharma cuts prices of Azmarda by 50 percent Dr. Nandita Mohan8 Dec 2022 7:33 AM GMTMumbai: Treatment of Heart Failure will get more affordable in India, as makers of the heart failure drug Azmarda, JB pharma, has announced a...
JB Pharma slashes price of critical Heart Failure medicine AZMARDA (Sacubitril-Valsartan) by nearly 50 percent Ruchika Sharma5 Dec 2022 9:07 AM GMT"This move by JB will not only help reduce the cost of treatment but will also help enhance the productive years of patients and their quality of...
Managing Heart Failure in India with Sacubitril Valsartan: Lessons from Clinical Trials Dr. Prem Aggarwal19 Sep 2022 6:05 AM GMTChronic Heart Failure (CHF) is a complex syndrome in which the heart cannot provide adequate cardiac output to meet the body's metabolic requirements...
Managing heart failure with sacubitril-valsartan: Why ARNIs stand out? dr. Abhimanyu Uppal30 July 2022 5:48 AM GMTHeart failure (HF) is a major economic and health burden worldwide, characterized by the presence of dyspnea or limited exertion due to impaired...
JBCPL records growth rate of 29 percent in FY2021-22 Ruchika Sharma9 May 2022 4:45 AM GMTBrands of JBCPL are ranked in the top 300 pharmaceutical brands of the Indian Pharmaceutical Market.
JBCPL gets trademark assignment of heart failure drug Azmarda from Novartis Roshni Dhar5 April 2022 12:15 PM GMTJB Chemicals and Pharmaceuticals (JBCPL) has recently announced that the company has approved the assignment of trademark for Azmarda indicated for...
Health Bulletin 5/April/2022 Roshni Dhar5 April 2022 11:55 AM GMTHere are the top health stories for the day:1 crore refunded to patients overcharged for Covid treatment at private hospitals The civic administration...
JBCPL gets trademark assignment of HF drug Azmarda from Novartis for Rs 246 crores Ruchika Sharma4 April 2022 5:52 AM GMTMumbai: JB Chemicals and Pharmaceuticals (JBCPL) has recently announced that the company has approved the assignment of trademark for Azmarda...
